Orexo is a specialty pharmaceutical company with commercial operations in the United States and R&D in Sweden developing improved treatments using proprietary drug delivery technology. The company is commercializing its proprietary product, Zubsolv® sublingual tablets, for treatment of opioid dependence, in the US. The Zubsolv sublingual tablet is an advanced formulation of buprenorphine and naloxone using Orexo’s extensive knowledge in sublingual technologies. Orexo has a portfolio of additional two approved and revenue generating products currently marketed under license in the US, EU and Japan.

Read the Report

  October 20, 2016  

    Interim Report

Link to the AudioCast

   October 20, 2016  
  presenting the
Q316 report

Press releases

1 The press release does not constitute information that Orexo has an obligation to disclose under the EU Market Abuse Regulation, the Securities Market Act or the Financial Instruments Trading Act